Wednesday, February 10, 2010, 8:43am EST - Canadian Markets open in 47 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Rosetta Genomics, Ltd. (ROSG)

 On Feb 9: 1.61 USD   0.00 (0.00%)  
MORE ON ROSG
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Rosetta Genomics Ltd. (NGM:ROSG) Delayed quote dataEdit
Last Trade: 1.61 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 1.61
Open: N/A
Bid: N/A
Ask: 1.97 x 2700
1y Target Est: N/A
Day's Range: N/A - N/A
52wk Range: 1.59 - 3.80
Volume: 0
Avg Vol (3m): 90,725.4
Market Cap: 22.82M
P/E (ttm): N/A
EPS (ttm): -0.87
Div & Yield: N/A (N/A%)
Rosetta Genomics, Ltd. (ROSG)
1d  5d  3m  6m  1y  2y  5y 
 Add ROSG to Portfolio   Download Data

HEADLINES
• Rosetta Genomics Announces Issuance of Three U.S. Patents
Business Wire (Wed, Feb 3)
• Rosetta Genomics Fortifies Patent Position with U.S. Allowance of Claims Covering Human microRNAs miR-21 and hcmv-miR-UL112
Business Wire (Fri, Jan 29)
• Rosetta Genomics Ltd. Closes $5.1 Million Financing; Will Support Ongoing Development of microRNA-based Diagnostic Pipeline
Business Wire (Tue, Jan 19)
• Medifast, Rosetta Genomics: Biggest Price Decliners (MED, ROSG)
at The Wall Street Journal Online (Thu, Jan 14)
• LaBranche, Rosetta Genomics: Early Volume Plays
at TheStreet.com (Thu, Jan 14)
• Rosetta Genomics Ltd. to Raise $5.1 Million in Registered Direct Offering
Business Wire (Wed, Jan 13)
• Rosetta Announces that Johns Hopkins University Researchers Demonstrate miRview squamous Classifies Non-Small Cell Lung Cancer with Extremely High Deg
Business Wire (Wed, Jan 13)
• Rosetta Genomics Stockholders Elect Two New Directors at Annual Meeting
Business Wire (Tue, Dec 22)
• ROSETTA GENOMICS LTD Earnings, Business Update & Pipeline Progress Call scheduled for 8:30 am ET today
CCBN (Fri, Dec 18)
• Rosetta Genomics Reports Third Quarter Financial Results, Provides Business Update
Business Wire (Fri, Dec 18)
More Headlines for ROSG...
ANALYST
EPS Est (next year) () : N/A
EPS Est (in 2 years) () : N/A
Avg Rec (current)*: N/A
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices